AI's Venture Capital Concentration and Its Hidden Costs

U.S. startups raised roughly $413 billion in venture capital during the first half of 2026, more than in all of 2025. According to PitchBook, AI companies received 86% of that money, and megadeals, defined as rounds of $100 million or more, accounted for nearly 88% of it.

The largest recipients are frontier AI labs, the companies that build the most capable general-purpose models. OpenAI closed a $122 billion funding round at an $852 billion post-money valuation in March, and Anthropic raised $65 billion at a $965 billion post-money valuation in May, as Beige Media reported in September.

Those prices assume the labs will sustainably capture a large share of the economic value that AI creates. If that assumption fails, the consequences could reach well beyond the labs.

Venture funds depend on limited-partner commitments, and the distributions generated by earlier funds help determine whether those investors can recommit to new ones. Today's concentration therefore affects two groups: companies outside AI competing for early-stage capital now, and companies in every sector that will depend on venture funds raised later in the decade.

Key Points

AI companies took 86% of U.S. venture dollars in the first half of 2026, and megadeals of $100 million or more took nearly 88%.
Frontier AI labs face price competition from cheaper and open-weight models, which may shift more of AI's economic value to the businesses that apply it.
Headline funding has risen in biotech, climate, and crypto even as early-stage biotech rounds, climate deal counts, and crypto fund formation weakened.
Defense and robotics are counterexamples, supported by government demand and the "physical AI" investment narrative.
Venture funds depend on exits to return cash to investors, so a repricing of AI valuations could reduce the capital available for startups later in the decade.
Companies outside frontier AI that own data, operations, and customer relationships may capture more of AI's gains as inference becomes cheaper and more widely available.

A Market Built Around One Theory of Value

The concentration has accelerated quickly. AI represented about 65% of U.S. venture deal value in 2025 while accounting for under 40% of deals, according to the PitchBook-NVCA Venture Monitor.

Deals below $100 million, which still make up most of the market by count, fell from about 44% of deployed value in 2024 to about one-eighth in the first half of 2026, SiliconANGLE reported.

PitchBook's analysts have warned that a market this dependent on a single theme faces a broad correction if AI growth or returns disappoint. Venture returns follow a power law, meaning a small number of winning companies generate most of the gains.

Even if AI succeeds as a technology, PitchBook noted, returns will concentrate in a few companies and leave many that raised at high prices exposed.

The central question concerns where AI's value will be captured. Frontier labs sell model access largely by the token, a small unit of text that a model processes, and the cost of reaching a fixed level of capability has fallen sharply.

The Stanford AI Index found that the inference cost of performance comparable to GPT-3.5 fell more than 280-fold between late 2022 and late 2024.

Open-weight models, whose parameters are published so that any company can host them, add further price competition. Enterprises have also begun designing systems that let them switch model suppliers through common interfaces, a pattern Beige Media examined in its analysis of frontier token pricing.

Each pricing change or usage restriction gives customers a reason to qualify alternative suppliers.

These forces allow AI to raise productivity across the economy while limiting the share of that gain collected by model providers. Continued improvement in frontier capability does not settle the matter, because frontier capabilities can diffuse into cheaper alternatives as competitors catch up.

Much of the surplus may instead settle with the businesses that own the data, operations, and customer relationships to which AI is applied.

Funding Rises While Early Stages Thin

Concentration can draw capital away from other sectors through specific channels, and corporate venture activity offers one visible example.

Corporate venture arms and other corporate investors participated in about 21% of U.S. deals in the first half of 2026, their lowest share in a decade. This shift occurred as companies grappled with rising AI costs and moved toward larger strategic deals, according to PitchBook reporting.

New fund formation has also contracted. U.S. venture fundraising fell about 34% in 2025 to $67 billion, the lowest total in nine years, according to the National Venture Capital Association.

Some frontier capital comes from sovereign funds, cloud providers, and strategic investors and is not necessarily fungible with capital that would otherwise back agriculture or drug discovery. The opportunity cost operates at the margin, where fund commitments and investor attention are limited.

Biotech shows how rising sector totals can conceal thinning early stages. Among companies backed by the 26 venture firms tracked by BioPharma Dive, funding for drug developers posted its strongest first half since 2022.

Yet about two-thirds of tracked rounds went to companies that already had a drug candidate in human trials. Seed and Series A rounds fell to their lowest first-half count in a decade, and early-stage capital dropped about 15% from a year earlier, BioCentury found.

Investors are directing limited risk appetite toward drug programs that have already passed early scientific tests. If that pattern persists, the companies that would supply new drug candidates a decade from now may absorb the shortfall.

Climate technology shows another version of the same pattern. Climate venture funding rose about 55% to roughly $26 billion in the first half of 2026, and low-carbon data centers took 34% of it, up from 3% a year earlier, according to Currence data published by CTVC.

Deal count fell to a five-year low, while equity funding for carbon-focused startups dropped about 61%. A large part of the sector's recovery is tied to infrastructure for the AI data-center buildout.

Capital Follows Independent Demand

Investors deployed about $5.7 billion into crypto companies in the second quarter of 2026, according to Galaxy Research. Later-stage companies received about 78% of the money, and trading, exchange, investing, and lending businesses drew nearly three-fifths.

Only five new crypto venture funds raised capital, the fewest in a quarter since Q3 2019.

Galaxy said spot exchange-traded products and digital-asset treasury companies may be siphoning allocator attention and dollars from venture funds and startups. This gives institutions liquid alternatives to long-duration venture exposure.

Research-oriented protocol development, which depends on patient early-stage capital, faces a fund-formation environment closer to 2019 than to the peak of the previous cycle.

Agriculture technology and digital health show the same compression. Agtech investors completed about 263 deals in the first half of 2026, a pace that implies roughly a 40% annual decline in deal activity, according to PitchBook data reported by AgNavigator.

In digital health, rounds of $100 million or more took about 45% of capital from just over 8% of transactions, Rock Health found.

Defense technology is the clearest exception. PitchBook's defense-and-defense-adjacent category, which includes space, quantum, semiconductors and microelectronics, advanced manufacturing, and energy, attracted about $35.6 billion in the first half of 2026, according to data provided to Tectonic Defense.

Early-stage value rose 47% while later-stage value fell 69%. Government buyers with appropriated budgets provide a source of demand independent of AI valuations, a dynamic Beige Media described in its reporting on procurement-driven markets.

Robotics has drawn record funding by joining the AI narrative directly. Humanoid robotics startups raised about $11 billion through October 6, 2026, more than double the previous full-year record, with Chinese companies taking about 63% of the total, according to Dealroom.

The contrast suggests that sectors with government demand, independent commercial demand, or a credible role in the AI production chain can still attract substantial capital.

Spent Capital and the Recycling Problem

The money invested in AI does not disappear. It pays chipmakers, data center operators, and energy suppliers, along with the engineers who build the models.

That spending builds a capital stock concentrated in computing capacity. The opportunity cost is the productive capacity that alternative deployments of the same fungible capital might have built elsewhere.

Venture capital depends on a cycle. Limited partners, the pension funds, endowments, and other institutions that supply venture funds, receive cash when portfolio companies are sold or go public.

Those distributions replenish the liquidity that supports commitments to new funds. The National Venture Capital Association describes the sequence directly: fewer exits mean fewer distributions, weaker recommitments, fewer new funds, and less capital for startups.

That cycle was strained before any AI repricing. Net cash flows to limited partners ran nearly $200 billion negative from 2022 through 2025, according to PitchBook.

Carta's second-quarter 2026 data put median DPI at 0.37x for 2017-vintage funds and 0.15x for 2018-vintage funds. This leaves the typical fund from those years far short of returning paid-in capital in cash, according to Carta.

The 2021 funding peak shows what can happen to capital raised at high valuations. On the Forge secondary platform, startups whose last primary round came in 2021 or 2022 trade at median discounts of 59.1% and 54.1%, respectively.

In contrast, those that raised in 2025 or 2026 trade at discounts of 4.7% and zero, according to PitchBook figures reported by The Next Web. Flat and down rounds fell to 13.1% of deals, the lowest share since 2022.

Funds deployed at peak valuations can help determine how much capital limited partners are able or willing to recommit in the early 2030s.

If AI valuations reprice and eventual realizations disappoint, the opportunity cost could extend to funds that are never raised and to the seed rounds those funds would have written in sectors far from AI. The exposure can compound from one fund generation to the next.

How the Valuations Could Resolve

Broadly, concentrated AI valuations can resolve in three ways. A markdown or down round recognizes part of a valuation gap inside private portfolios and can weaken eventual fund returns. A public listing gives private valuation risk a route to wider distribution if public investors accept comparable pricing.

OpenAI and Anthropic have both filed to go public; Anthropic has since disclosed an IPO prospectus.

The third path is for the labs to grow into their valuations through continued growth and eventual profitability. That outcome remains possible, though price competition from cheaper and open-weight models works against the margins required to support it.

Secondary-market pricing for recent rounds currently reflects little risk of a reset.

Investor returns and economic benefits can diverge. AI could raise productivity across many industries while the investors who priced model providers as the principal beneficiaries realize losses if competition transfers much of the gain to customers and downstream businesses.

That divergence points to an investment case in less-favored sectors. Companies that own clinical data, physical operations, or established customer relationships can adopt cheaper AI on their own terms while raising money without the same frontier-AI premium.

Acquisitions provide exit routes: digital health recorded 115 acquisitions in the first half of 2026, according to Fierce Healthcare. All 15 agtech exits in the second quarter came through mergers and acquisitions, according to CropLife.

The opportunity has a time limit. These sectors face limited capital now and could face less if the recycling cycle weakens further.

The advantage belongs less to companies that merely use AI than to those that can apply increasingly commoditized intelligence to assets, expertise, and relationships that remain scarce.

Development economists use the term Dutch disease for a boom that appreciates a country's real exchange rate and reallocates capital and labor toward the booming sector and nontradable industries, weakening other tradable sectors.

The venture market is not a literal case, but the resource-reallocation analogy is useful. Computing capacity, electric power, and engineering talent are flowing toward a single investment theme.

The record totals of 2026 measure how much capital has entered venture markets. They do not show how narrow the base of funded companies has become.

The next decade of startup funding outside AI could be shaped in part by how today's concentrated valuations resolve.